You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

October 25, 2016

Effects of the TPP on Vietnam’s Pharmaceutical Industry

Subscribe to Updates
Vietnam Pharma Update

On February 4, 2016, Vietnam and 11 other countries signed the Trans-Pacific Partnership (TPP). The TPP includes Australia, Brunei, Canada, Chile, Japan, Malaysia, Mexico, New Zealand, Peru, the United States, Vietnam, and Singapore—countries which represent 36 percent of global GDP and more than 25 percent of world trade. Though the prospects of a quick and smooth ratification of the treaty have dimmed considerably, thanks to election-year politicization in the United States, if and when the TPP is finally ratified by its various participants, it will have a major impact on business in Vietnam—including the pharmaceutical industry.

The TPP will affect the pharmaceutical industry largely through its investment protections and intellectual property regime. Like other free-trade agreements, the TPP promotes foreign investment by requiring its member states to provide protections over investments originating from other TPP member countries. Importantly, intellectual property rights are considered a “covered investment” under the TPP. In other words, Vietnam is obligated to protect a pharmaceutical company’s IP rights in accordance with the TPP. In addition to these investment protections, the TPP also contains an entire subchapter dedicated to the pharmaceutical industry, including the treatment of patents.

Investment Protections

While most of the investment protection under the TPP would apply to all companies equally, pharmaceutical companies should pay particular attention to the following.

National Treatment and Most-Favored Nation Treatment. The TPP requires Vietnam to treat investors from other TPP member states (TPP Investors) the same way it would treat domestic investors in similar circumstances. In other words, Vietnam is required to give “national treatment” to TPP Investors. In addition, Vietnam must treat such covered investments the same way it would treat locally owned projects. The TPP also requires Vietnam not to discriminate against any foreign investor. For example, if an American pharmaceutical company owns a patent in Vietnam, that patent must be treated the same way as if a Vietnamese party held the patent. 

Expropriation. The TPP prohibits member states from expropriating investments. In other words, Vietnam would generally be prohibited from expropriating or nationalizing a pharmaceutical company’s IP rights. However, expropriation is allowed if it is for a “public purpose,” such as compulsory patent licensing in a public health emergency. In such case, Vietnam must promptly provide compensation to the investor that is equivalent to market value. The TPP further mandates that any expropriation must be done without discrimination.

Performance Requirements. The TPP prohibits Vietnam from requiring an investment project to use or implement certain “preferred” commitments or content. For example, Vietnam cannot enact legislation requiring a foreign pharmaceutical company to use only locally sourced materials or technology in its toll manufacturing, or to export a specific percentage of goods. Other prohibitions include forcing an investor to adopt a specific royalty rate under a license contract or a specific term of a license contract.

Important exceptions to this provision exist. The license restrictions do not apply to license agreements between a foreign investor and the Vietnamese government. In addition, the government is allowed to mandate performance requirements with regard to government procurement, certain investment privileges and benefits, and preferential tariffs or quotas. Other general exceptions also apply, such as legislation to protect human and environmental health.

Patents

Under Article 5.3 of Vietnam’s Law on Intellectual Property, if a regulation in an international convention of which Vietnam is a member differs from the respective regulation of the IP law, then the regulation in the convention would apply. Based on this, the Law on Intellectual Property will likely be adjusted to be consistent with the TPP. The following articles in the current regulations are not consistent with the respective regulations of the TPP:

Patentable Subject Matter. Under the TPP, patents are available for “use inventions,” that is, those claiming at least one of the following: new uses of a known product, new methods of using a known product, or new processes of using a known product. A member state may limit those new processes to those that do not claim the use of the product. Currently, the Vietnam Patent Office rejects use inventions in general, though it lacks convincing legal grounds. In light of the TPP, Vietnam’s Patent Office should change its treatment of use inventions. However, it is unclear—even with the change—whether new indications or new methods, such as new dosing, will be patentable.

Patent Term Adjustment for Patent Office Delays. According to the TPP, a patent term can be adjusted to compensate for unreasonable delays in a member state’s issuance of patents. The transition period is five years, which can be extended for up to one additional year, meaning that it could become effective in 2023 or 2024. This issue is not addressed in Vietnam’s current regulations.

Data Protection for Drugs. The provisions of the TPP on data protection for drugs differ from current Vietnamese law. Under the current regulations, within five years from the date of marketing authorization of the data-protected drug, no marketing authorization can be granted for other dossiers referring to the protected trial data. The TPP also provides a period of at least five years from the date of marketing authorization during which a third party cannot market a product on the basis of: (1) protected data; or (2) the marketing approval granted. Therefore, there could be some adjustments in the applicable laws of Vietnam related to data protection for drugs to make the data protection more reliable in practice. The transition period is ten years, which can be extended for up to two additional years, meaning that it could become effective in 2028 or 2030.

Outlook

The TPP is expected to create new business opportunities in Vietnam for pharmaceutical companies. The investment protections will reduce risk and increase confidence, which will add to investment inflows. Pharmaceutical companies would also have increased predictability and protections with respect to their IP rights. Both Vietnam and pharmaceutical firms will benefit.

Download Full Article
Related Professionals

Industries

Life Sciences

Practices

Corporate/M&A

Intellectual Property

Regulatory Affairs

Location

RELATED INSIGHTS​ 

October 25, 2023
One significant development in the health sector in Indonesia is the use of information technology and communication in the implementation of health efforts—particularly digital health services such as telehealth and telemedicine integrated into the country’s National Health Information System. This development was addressed in a major new piece of legislation for the healthcare sector in Indonesia. Enacted in August 2023, Law No. 17 of 2023 concerning Health (the “Health Law”) provides the updates needed to support the development of healthcare services in Indonesia. Under the Health Law, health information system (HIS) providers must: Carry out processing of data and health information in the territory of Indonesia, except for certain limited and specific processing activities that may be conducted outside Indonesia when permitted by the relevant authorities and in compliance with relevant regulations. Ensure the reliability of its HIS, including availability, security, maintenance, and integration with Indonesia’s National Health Information System. Provide quality health data and information. Process data and health information, which includes planning, collection, storage, inspection, transfer, utilization, and destruction. Record its data- and information-processing history. Protect every person’s data and health information. Obtain approval from the relevant personal data subject or comply with relevant regulations if the processing of data and health information involves an individual’s health data. Inform the data owner if there is a failure to protect data and individual health information. The Health Law’s personal data protection requirements listed above appear to be aligned with the provisions in Law No. 27 of 2022 concerning Personal Data Protection (the “PDP Law”). Under this law, data and information relating to health are identified as “specific personal data,” the processing of which carries a high potential risk of impacting the relevant personal data subject. In the implementation of digital health services, patients’ personal data or medical records
Read More
October 19, 2023
Cambodia’s Law on Food Safety came into force on June 8, 2022. This law has been widely regarded as a major legal development of the food safety framework in Cambodia, providing new rules, clarifying existing rules, and setting a clear framework for its implementation and enforcement. In addressing some of the key features of this new law shortly after it was passed in 2022, we remarked that we eagerly await implementing regulations. Since then, various regulations have been adopted, such as two regulations (Sub-Decree No. 13 and Prakas No. 80) on food surveillance, recalls, and seizure. These implementing rules are essential in ensuring that enforcement officers can remove noncompliant and unsafe foods from the market. Another key aspect of the Law on Food Safety is that it requires Khmer-language labeling on prepackaged food products. There has been a notable increase in the inclusion of Khmer labeling on food products in the market since June 2022, but noncompliance is still considerable, especially for imported foods. Further interesting labeling rules set by the Law on Food Safety include a requirement to provide nutrition information. This requirement has not yet been widely adopted, with many in the industry highlighting that the details of this labeling requirement are not clear. Indeed, the relevant article of the Law on Food Safety itself only sets the requirement for food products to bear nutrition labeling and does not spell out what detailed information should be provided or in what manner. However, a prakas (ministerial regulation) adopted months prior to the Law on Food Safety does set out clear guidance on nutrition labeling. As long as this earlier regulation is not replaced or abrogated, and as far as it does not conflict with later laws or regulations, it can be relied upon for guidance. What are the
Read More
September 20, 2023
Thailand is preparing to open its first renewal period for drug marketing authorizations (MAs) since the passage of the Drug Act (No. 6) B.E. 2562 (2019). Before 2019, MAs for pharmaceuticals and vaccines in Thailand had lifelong validity. The 2019 Drug Act stipulated that all new MAs would be valid for seven years and could be renewed. The 2019 law also set out expiration dates for existing pharmaceutical products registered and approved prior to the implementation of the law (i.e., before October 13, 2019): Drug MAs issued before January 1, 1997, expire on October 13, 2024. Drug MAs approved between January 1, 1997, and December 31, 2007, expire on October 13, 2026. Drug MAs approved between January 1, 2008, and October 13, 2019, expire on October 13, 2028. Based on these dates, the first renewal period for drug MAs will commence in the fourth quarter of 2023. To facilitate the renewal process, the Thai Food and Drug Administration (FDA) has publicized draft regulations and notifications on the required application form and documents, the rules and conditions, and the process for renewing an MA. In May 2023, the Thai FDA issued Ministerial Regulation Re: Renewal of Drug MA Licenses B.E. 2566 (2023) to prescribe the essential requirements for filing a renewal application: To renew a drug MA, holders must submit their renewal application to the Thai FDA within the one-year period before the MA’s expiration date. Renewal applications can only be submitted online via the Thai FDA’s electronic system. The Thai FDA will grant approval for an MA renewal if the following conditions are satisfied: The documents in relation to efficacy and safety are up-to-date, accurate, and in accordance with academic principles. The specification and analytical method comply with the official pharmacopeias as prescribed in the Drug Act, as amended.
Read More
September 15, 2023
In May 2023, Thailand issued a regulation on conditional approval for emergency use of medicinal products, replacing a series of similar notifications that had been issued to aid mitigation efforts during the COVID-19 pandemic. During the pandemic, regulatory authorities worldwide—including the Thai Food and Drug Administration (FDA)—reshaped the approval pathway for emergency drugs intended for the treatment of COVID-19. The Thai FDA published five Notifications Re: Conditional Approval for the Emergency Use of Medicinal Products to outline the registration requirements and channels of distribution for drugs intended for the diagnosis, treatment, or prevention of COVID-19. As the threat from COVID-19 was receding, the Thai FDA saw fit to prepare for the potential emergence of other serious communicable diseases by enabling the supply of timely medications for disease diagnosis, treatment, and prevention. The Thai FDA therefore cancelled the five COVID-19-related emergency use notifications, which were published in 2020 and 2022, and replaced them with the Notification Re: Conditional Approval for Emergency Use of Medicinal Products published in May 2023. Under the May 2023 FDA notification on emergency use, conditional approval can be applied to drugs supported by empirical scientific evidence demonstrating their capacity to diagnose, treat, alleviate, cure, or prevent a serious communicable disease. The drugs eligible for approval under this new emergency pathway include novel drugs that are not yet approved in Thailand, as well as existing drugs approved in Thailand but recently discovered to have additional potential indications for the diagnosis, treatment, alleviation, cure, or prevention of a serious communicable disease. Distribution The 2023 FDA notification also clearly defines permissible distribution channels based on the dosage form of drug products: Vaccines can be distributed to governmental organizations that have a duty to prevent or treat diseases, such as the Thai Red Cross Society (TRCS), the Government Pharmaceutical Organization
Read More